Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Multisite clinical trial will compare three FDA-approved drugs for Rett syndrome treatment

Written by | 5 Feb 2024

Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for… read more.

Gabapentinoid use appears to raise risk of COPD exacerbation

Written by | 16 Jan 2024

Researchers from a large retrospective study report that, among patients diagnosed with COPD (chronic obstructive pulmonary disease), gabapentinoid use appears to be associated with an increase in the… read more.

Nearly half of oncology drugs approved since 1998 are precision therapies

Written by | 20 Oct 2023

Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of… read more.

New research may make future design of nanotechnology safer with fewer side effects

Written by | 13 Oct 2023

A new study may offer a strategy that mitigates negative side effects associated with intravenous injection of nanoparticles commonly used in medicine. The study was published today in Nature… read more.

New orally available drug for spinal cord injury found to be safe and tolerable in healthy participants

Written by | 12 Aug 2023

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has demonstrated the safety and tolerability of a new drug treatment designed as… read more.

Specialty drugs accounted for most new product launches in the past decade. Why do we know so little about how clinical studies influence their diffusion?

Written by | 20 Jun 2023

Researchers from McGill University and Ontario Tech University published a new Journal of Marketing article that examines the drivers of specialty drug diffusion. The study, forthcoming in the Journal of Marketing, is titled “Scientific Evidence… read more.

Metformin lowers risk of long COVID

Written by | 10 Jun 2023

Treatment with the diabetes drug metformin immediately after testing positive for the SARS-CoV-2 virus lowers the risk of developing long COVID by 41%. Researchers reported this finding on… read more.

Using AI to create better, more potent medicines

Written by | 2 Jun 2023

While it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, a new study suggests that using generative artificial intelligence… read more.

Journal of Pharmaceutical Analysis studies shine the light on advancements in pharmaceutical analytical techniques and overcoming chemoresistance

Written by | 1 Jun 2023

Research into new drug development is ongoing at a very fast pace globally. In keeping with newer remedies entering the market, there is a need for optimizing existing… read more.

Artificial intelligence in pharmaceutical sciences revolutionizes drug research and development

Written by | 27 May 2023

Scientists have long been challenged by the complex process of drug discovery and development, with investments that often go unrewarded. However, with the advancement of experimental technology and… read more.

Tadalafil shows potential as a diabetes treatment

Written by | 17 May 2023

In a small feasibility study, subjects with type 2 diabetes achieved significant improvement in long-term blood sugar levels following treatment with high-dose tadalafil, an erectile dysfunction drug.  Tadalafil… read more.

Atogepant shows efficacy for prevention of migraine

Written by | 14 May 2023

Atogepant, an oral drug approved in the US for the prevention of episodic migraine treatment appears to also be effective for the prevention of chronic migraine. The findings of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.